A pilot study of intravitreal bevacizumab for the treatment of central serous chorioretinopathy (case reports).

Background: We report the use of intravitreal bevacizumab as a new option in the treatment of central serous chorioretinopathy (CSC).

Methods: Five eyes with retinal pigment epithelium (RPE) leaks secondary to CSC received intravitreal bevacizumab (2.5 mg/0.